Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1999 • 8,737 citations

A review of human carcinogens—Part B: biological agents

2009 • 2,713 citations

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

2010 • 2,440 citations

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

2006 • 1,766 citations

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

2004 • 1,624 citations

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

2009 • 1,580 citations

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

2007 • 1,287 citations

Persistence of Type-Specific Human Papillomavirus Infection among Cytologically Normal Women

1994 • 695 citations

Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis

2008 • 675 citations

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

2011 • 654 citations

Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection

2007 • 652 citations

The carcinogenicity of human papillomavirus types reflects viral evolution

2005 • 552 citations

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

2011 • 472 citations

Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica

2013 • 438 citations

A Longitudinal Study of Genital Human Papillomavirus Infection in a Cohort of Closely Followed Adolescent Women

2004 • 415 citations

Incidence, Duration, and Determinants of Cervical Human Papillomavirus Infection in a Cohort of Colombian Women with Normal Cytological Results

2004 • 395 citations

Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women

2013 • 389 citations

Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis

2012 • 389 citations

Persistent Human Papillomavirus Infection and Cervical Neoplasia: A Systematic Review and Meta-Analysis

2008 • 387 citations

Incidence Trends of Adenocarcinoma of the Cervix in 13 European Countries

2005 • 374 citations

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years

2009 • 347 citations

Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine

2011 • 314 citations

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials

2015 • 283 citations

Economic evaluation of human papillomavirus vaccination in the United Kingdom

2008 • 279 citations

Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV

2015 • 256 citations

Human Papillomavirus Genotype Distributions: Implications for Vaccination and Cancer Screening in the United States

2009 • 244 citations

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine

2014 • 227 citations

Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

2013 • 205 citations

HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases

2014 • 189 citations

Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine

2012 • 183 citations

Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial

2011 • 181 citations

Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types

2014 • 173 citations

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

2014 • 170 citations

High incidence of cervical human papillomavirus infection in women during their first sexual relationship

2002 • 167 citations

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women

2010 • 164 citations

Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica

2011 • 163 citations

Highly Effective Detection of Human Papillomavirus 16 and 18 DNA by a Testing Algorithm Combining Broad-Spectrum and Type-Specific PCR

2006 • 157 citations

Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland

2014 • 156 citations

Human Papillomavirus Infection and Reinfection in Adult Women: the Role of Sexual Activity and Natural Immunity

2010 • 151 citations

The health care costs of cervical human papillomavirus–related disease

2004 • 138 citations

Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV‐16/18

2011 • 124 citations

Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England

2013 • 119 citations

Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model

2011 • 118 citations

Efficacy of the HPV-16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial

2014 • 108 citations

Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial

2015 • 106 citations

Risk of preterm delivery with increasing depth of excision for cervical intraepithelial neoplasia in England: nested case-control study

2014 • 98 citations

Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK

2006 • 95 citations

Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination

2014 • 95 citations

Prevention of HPV-Related Cancers in Norway: Cost-Effectiveness of Expanding the HPV Vaccination Program to Include Pre-Adolescent Boys

2014 • 91 citations

HPV Infections in Adolescents

2007 • 82 citations

Efficacy of Human Papillomavirus Vaccines

2009 • 78 citations

Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation

2013 • 78 citations

Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging

2015 • 77 citations

Incidence, Duration, and Reappearance of Type-Specific Cervical Human Papillomavirus Infections in Young Women

2010 • 77 citations

HPV vaccine efficacy in preventing persistent cervical HPV infection: A systematic review and meta-analysis

2007 • 65 citations

Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18–25 years: Results from a randomized controlled trial

2014 • 59 citations

Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths

2013 • 57 citations

Gardasil 9 joins the fight against cervix cancer

2015 • 56 citations

Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix®

2012 • 49 citations

Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial

2015 • 45 citations

Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium

2008 • 43 citations

Antibody avidity measurements in recipients of Cervarix® vaccine following a two-dose schedule or a three-dose schedule

2014 • 38 citations

Efficacy of Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Japanese Women Aged 20 to 25 Years

2010 • 37 citations

Efficacy of Human Papillomavirus Type 16/18 AS04-Adjuvanted Vaccine in Japanese Women Aged 20 to 25 Years: Final Analysis of a Phase 2 Double-Blind, Randomized Controlled Trial

2010 • 33 citations

A Human Papilloma Virus Testing Algorithm Comprising a Combination of the L1 Broad-Spectrum SPF ₁₀ PCR Assay and a Novel E6 High-Risk Multiplex Type-Specific Genotyping PCR Assay

2013 • 32 citations

Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women

2012 • 30 citations

Impact of Human Papillomavirus Vaccination on Cervical Cytology Screening, Colposcopy, and Treatment

2013 • 30 citations

Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women

2014 • 30 citations

Health and Economic Burden of HPV-related Diseases in Singapore

2012 • 26 citations

The burden and costs of prevention and management of genital disease caused by HPV in women: A population-based registry study in Finland

2013 • 24 citations

Vaccinating Women Previously Exposed to Human Papillomavirus: A Cost-Effectiveness Analysis of the Bivalent Vaccine

2013 • 22 citations

Post Hoc Analysis of the PATRICIA Randomized Trial of the Efficacy of Human Papillomavirus Type 16 (HPV-16)/HPV-18 AS04-Adjuvanted Vaccine against Incident and Persistent Infection with Nonvaccine Oncogenic HPV Types Using an Alternative Multiplex Type-Specific PCR Assay for HPV DNA

2014 • 20 citations

Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru

2012 • 20 citations

Systematic Review and Meta-Analysis of L1-VLP-Based Human Papillomavirus Vaccine Efficacy against Anogenital Pre-Cancer in Women with Evidence of Prior HPV Exposure

2014 • 19 citations

Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica

2015 • 19 citations

Reduced Prevalence of Vulvar HPV16/18 Infection Among Women Who Received the HPV16/18 Bivalent Vaccine: A Nested Analysis Within the Costa Rica Vaccine Trial

2014 • 18 citations

Effect of Different Human Papillomavirus Serological and DNA Criteria on Vaccine Efficacy Estimates

2014 • 17 citations